NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

GRI Bio, Inc. (GRI) Stock Analysis

GRI Bio, Inc. (GRI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GRI

$2.88

+$0.59 (+25.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GRI with… →

GRI Key Statistics

As of Sep 4, 2026
Trading
Open
$2.34
Previous Close
$2.29
Day's Range
2.33–3.36
52-Week Range
1.36–80.36
Volume
7.42M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.55
Valuation
Market Cap
$6.30M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.55
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$11.96M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.19M
1-Year Return
−93.14%
Dividend and dates
Avg Volume
212.16K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GRI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−58.36%
2025−98.25%
2024−97.64%
2023−95.57%
2022−95.15%
2021 (partial year)−20.48%

As of September 4, 2026.

GRI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$11.96M—
2024$0.00−$8.21M—
2023$0.00−$13.04M—
2022$0.00−$3.22M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$11.98M−$11.96M—
2024$0.00—−$8.24M−$8.21M—
2023$0.00—−$11.39M−$13.04M—
2022$0.00—−$2.24M−$3.22M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GRI Valuation vs Biotechnology Median

Median of 656 stocks
MetricGRIBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values GRI Bio, Inc. (GRI) at $6.30M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 3 employees.

GRI last closed at $2.88 on September 4, 2026. That is +$0.59 (+25.76%) against the previous close. Over the past 52 weeks the price has ranged from $1.36 to $80.36. The latest close sits 111.76% above that 52-week low.

Financial Health

In fiscal 2025, GRI Bio, Inc. reported revenue of $0.00. The same year closed with a net loss of $11.96M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −3.55.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at −0.55. Annualized volatility over the trailing 5 years is 171.28%. The trailing one-year price return is −93.14%. Measured over 5 years, that is −95.16% a year compounded.

Growth & Income

The record shows no dividend for GRI.

The strongest complete calendar year on file is 2022 at −95.15%; the weakest is 2025 at −98.25%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −58.36% year to date.

Peer Comparison

GRI Bio, Inc. (GRI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GRI Bio, Inc. GRI $6.30M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. GRI Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About GRI Bio, Inc.

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Visit website →